CT of hepatocellular carcinoma in non-alcoholic fatty liver disease: imaging characteristics and int

来源 :肝癌研究(英文版) | 被引量 : 0次 | 上传用户:acxyvpfag
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Aim: To determine the computed tomography (CT) features of non-alcoholic fatty liver disease (NAFLD) associated hepatocellular carcinoma (HCC).Methods: In this institutional review board approved study, we reviewed 38 patients with NAFLD (68.4% male; mean age 63 years) with histology confirmed HCC and triphasic liver CT. CT images were independently reviewed by four readers blinded to clinical and pathology data. The reviewers assessed HCC for arterial phase hyper enhancement (APHE), portal venous phase washout (PVWO), delayed phase washout (DPWO), and enhancing capsule. Features of cirrhotic morphology and portal hypertension (PH) were also evaluated. The final CT features were determined by majority and a fifth reader reviewed cases lacking majority. Inter-rater agreement was determined by prevalence-adjusted kappa. Results: Mean HCC size was 3.6 ± 2.8 cm (range, 1.1-16.0 cm). The HCCs showed APHE in 92.1%, PVWO in 55.3%, DPWO in 81.6%, and enhancing capsule in 44.7%. Cirrhotic morphology was present in 65.8% and PH in 63.2%. Inter-rater agreement was moderate to almost perfect for APHE (0.74-1.0), cirrhosis (0.79-0.89), and PH (0.79-0.95), weak to perfect for DPWO (0.47-0.95) and poor for PVWO (0-0.42).Conclusion: NAFLD associated HCC demonstrate less frequent portal venous washout on CT which may affect their imaging diagnosis.
其他文献
目的观察汉语失语症患者的命名表现,以及患者对提示的反应,由命名的症状讨论命名的相关机制,并探索对失语患者有效的提示方法。材料与方法入选自2006年8月至2007年4月在中国
本文对CD44V6、β-catenin在骨肉瘤中的表达及其临床意义进行了研究。结果表明:CD44V6、β-catenin在骨肉瘤的阳性表达与骨肉瘤的发生、发展和转移密切相关,可能在骨肉瘤细胞侵
Hepatocellular carcinoma (HCC) is one of the top-ranking cancers worldwide and in Southeast Asia. The high propensity for tumor recurrence, distant metastasis a
Aim: According to the current guidelines, transarterial chemoembolization (TACE) remains the first-line therapies for hepatocellular carcinoma (HCC) patients at